Mounjaro, DailyMed (2026) FDA approves new medication for chronic weight management, US Food and Drug Administration (2023) Mounjaro, PDR Tirzepatide, StatPearls (2024) Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022-2025), Healthcare (Basel, Switzerland) (2025) Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity, Sleep Medicine (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
According to Dr Wedgeworth the side effects of melanotan II can include: nausea, abdominal pain, anxiety, flushing, dizziness, headaches and stomach pain
Memantine in the treatment of binge eating disorder: an open-label, prospective trial
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, is a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes management and weight loss
In some instances, they can influence hunger
Long-term safety data may still be emerging